Lerdelimumab
Jump to navigation
Jump to search
Template:Short description Template:Drugbox Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.
It was being developed to reduce scarring after glaucoma drainage surgery.[1] Development was stopped in late 2005 after unsuccessful trial results for that condition.[2]
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".
Script error: No such module "Navbox". Script error: No such module "Navbox". Template:TGFβ receptor superfamily modulators